atazanavir sulfate has been researched along with 2019 Novel Coronavirus Disease in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 13 (100.00) | 2.80 |
Authors | Studies |
---|---|
Amri Male, P; Ezoji, K; Latifi, K; Mohammadnia-Afrozi, M; Sadeghi Haddad Zavareh, M; Seyfi, S | 1 |
Tsanni, A | 1 |
Abdi, A; Bavand, A; Farahani, E; Mazaherpour, H; Mazaherpour, S; Ramezani, A; Sofian, M | 1 |
Elhadad, H; Hien, NM; Huy, NT; Tam, DNH; Tran, L | 1 |
Atefi, N; Baghestani, A; Goodarzi, A; Khodabandehloo, N; Mahdi, Z; Najar Nobari, N; Riahi, T; Seirafianpour, F; Talebi Taher, M; Valizadeh, R | 1 |
Afshar, H; Aloosh, O; Emamikhah, M; Kalantari, S; Lotfi, T; Moghaddasi, M; Sadeghipour, A; Yassin, Z | 1 |
Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS | 1 |
Demirkan, K; Fırat, O; Yalçın, N | 1 |
Alves, CR; Bozza, FA; Bozza, PT; Cardoso Soares, V; Carels, N; da Silva Gomes Dias, S; de Freitas, CS; Ferreira, AC; Fintelman-Rodrigues, N; Matos, AR; Mattos, M; Miranda, MD; Ribeiro Lima, C; Sacramento, CQ; Siqueira, MM; Souza da Silva, F; Souza, TML; Temerozo, JR | 1 |
Abbasian, L; Davoudi-Monfared, E; Ghaderkhani, S; Ghiasvand, F; Hasannezhad, M; Khalili, H; Mohammadi, M; Nabiee, M; Nourian, A; Rahmani, H; Sadeghi, S; Seifi, A; Yekaninejad, MS | 1 |
Alhajj, R; Aygün, İ; Kaya, M | 1 |
Adeagbo, BA; Adebiyi, AO; Adefuye, BO; Akinloye, A; Bolaji, OO; Fagbamigbe, AF; Fowotade, A; Happi, C; Ladipo, OT; Ojo, TO; Olagunju, A; Olagunju, OI; Olagunoye, A; Onayade, A; Owen, A; Rannard, S | 1 |
Alimohamadi, Y; Fard, SR; Kalantari, S; Maleki, D; Minaeian, S; Taher, MT; Yassin, Z | 1 |
1 review(s) available for atazanavir sulfate and 2019 Novel Coronavirus Disease
Article | Year |
---|---|
Identifying side effects of commonly used drugs in the treatment of Covid 19.
Topics: Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Heparin; Humans; SARS-CoV-2 | 2020 |
4 trial(s) available for atazanavir sulfate and 2019 Novel Coronavirus Disease
Article | Year |
---|---|
Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial.
Topics: Acetylcysteine; Antiviral Agents; Atazanavir Sulfate; C-Reactive Protein; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Inflammation; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2 | 2023 |
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxychloroquine; Intensive Care Units; Interferon beta-1a; Length of Stay; Lopinavir; Male; Middle Aged; Neoplasms; Pandemics; Patient Safety; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Clinical Trials, Phase II as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Drug Administration Schedule; Drug Combinations; Drug Repositioning; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nigeria; Nitro Compounds; Pilot Projects; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Standard of Care; Thiazoles; Treatment Outcome; Viral Load; Young Adult | 2021 |
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome | 2021 |
8 other study(ies) available for atazanavir sulfate and 2019 Novel Coronavirus Disease
Article | Year |
---|---|
Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients.
Topics: Adenosine Monophosphate; Aged; Alanine; Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Immunization, Passive; Inpatients; Intensive Care Units; Interferon beta-1a; Interferon beta-1b; Male; Middle Aged; Patient Discharge; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Treatment Outcome | 2021 |
African scientists race to test COVID drugs - but face major hurdles.
Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxylamines; Imidazoles; Ivermectin; Naphthyridines; Nitro Compounds; Pregnenediones; Pyrazines; Pyrrolidines; Ritonavir; Sample Size; Thiazoles; Valine; World Health Organization | 2021 |
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
Topics: Aged; Antiviral Agents; Arrhythmias, Cardiac; Atazanavir Sulfate; Bilirubin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Length of Stay; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2; Treatment Outcome | 2022 |
Evaluation of COVID-19 protease and HIV inhibitors interactions.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; Darunavir; Humans; Lopinavir; Molecular Docking Simulation; Peptide Hydrolases; Protease Inhibitors | 2022 |
Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical - Paraclinical follow up study of a case.
Topics: Adult; Anti-Bacterial Agents; Anticonvulsants; Atazanavir Sulfate; Betacoronavirus; Brain; Consciousness Disorders; Coronavirus Infections; COVID-19; Diffusion Magnetic Resonance Imaging; Disease Progression; Encephalitis; Female; Glucocorticoids; HIV Protease Inhibitors; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Intensive Care Units; Levetiracetam; Lung; Magnetic Resonance Imaging; Methylprednisolone; Pandemics; Pneumonia, Viral; Pons; Respiration, Artificial; SARS-CoV-2; Seizures; Temporal Lobe; Thalamus; Tomography, X-Ray Computed | 2020 |
COVID-19 & antiepileptic drugs: Should we pay attention?
Topics: Anticonvulsants; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Carbamazepine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Lopinavir; Pandemics; Phenytoin; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Seizures | 2020 |
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Topics: Animals; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cell Death; Chlorocebus aethiops; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Cytokines; Drug Therapy, Combination; Humans; Inflammation; Lopinavir; Molecular Docking Simulation; Monocytes; Pandemics; Pneumonia, Viral; Protease Inhibitors; Ritonavir; SARS-CoV-2; Vero Cells; Viral Nonstructural Proteins; Virus Replication | 2020 |
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Intensive Care Units; Length of Stay; Male; Middle Aged; Prospective Studies; Ritonavir; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |